CXCR2 and neoplasm: In addition, a more recent study demonstrated that the small molecule PAD4 inhibitor JBI-589 can suppress primary tumour growth in mouse models by preventing neutrophil accumulation in the tumour microenvironment via downregulation of chemokine receptor CXCR2 expression [183].